ArticleBiochemistry and biophysics reports2026
Drug repositioning in metastatic prostate cancer based on protein- protein interaction network: Computational and in vitro analysis.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis is a big challenge for prostate cancer patients that reduces their overall survival from 98.2% to 30%. Therefore, it is important to find the underlying mechanism driving metastasis and find a drug that can prevent cell invasion, migration, and metastasis. Here, we analyzed publicly available expression data of primary and metastasized tissue of Prostate cancer extracted from the GEO database. The obtained Differentially Expressed Genes (DEGs) were used to construct the Protein-Protein Interaction (PPI) and functional networks. These DEGs were enriched in pathways such as blood vessel development, and mesenchyme migration which are involved in the process of Prostate cancer metastasis. The hub genes in the constructed PPI network were subjected to the DrugBank query to find candidate drugs with potential inhibitory effects on metastasis. We found that Artesunate can target three hub genes: CSRP1, FLNA, and TPM1. Finally, we validate this finding by in vitro assessments on the LNCaP cell line. We observed that 2.5 mg/ml Artesunate in the scratch assay reduced the scratch closure rate by about 50% compared to the control in 48 h. These findings suggest that Artesunate may be a promising therapeutic agent for inhibiting prostate cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.